Abstract:Objective: Apo2L/tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) is a potential anticancer drug that promotes apoptosis specifically in tumor cells. Because not all cancer cells are susceptible to Apo2L/TRAIL, the aim of our study was to determine whether non–small cell lung cancer cells can be sensitized by chemotherapeutic agents for Apo2L/TRAIL-induced apoptosis. In addition, endogenous expression levels of the caspase-inhibiting cellular protease caspase-8 inhibitory protein (C-FLIP) were measured to investigate partial resistance to Apo2L/TRAIL. Methods: Six human lung cancer cell lines (A549, NCI-H358, Calu1, Calu6, SkMes1, and SkLu1) were incubated with soluble Apo2L/TRAIL and two different concentrations each of cisplatin, paclitaxel, doxorubicin, 5-fluorouracil, and camptothecin. After 24 hours the rate of apoptosis was measured by annexin V/propidium iodide staining followed by FACScan analysis. Expression levels of C-FLIP in cell lines and lung cancer biopsy specimens were determined by Western blotting. Results: Treatment of lung cancer cells with Apo2L/TRAIL alone resulted in apoptotic cell death in four cell lines (P <.001). Combining Apo2L/TRAIL and chemotherapeutic agents enhanced the rate of apoptosis significantly. Statistical analysis revealed a synergistic effect of Apo2L/TRAIL in combination with 1.8 mmol/L camptothecin and 100 μmol/L cisplatin, each in four of the six cell lines (P <.002). Western blot analysis showed that sensitization to Apo2L/TRAIL did not correlate with the expression of cellular protease caspase-8 inhibitory protein. Furthermore, no increased cellular protease caspase-8 inhibitory protein levels relative to those in normal lung tissue could be found in non–small cell lung cancer specimens from 12 patients. Conclusion: Apo2L/TRAIL-induced apoptosis in non–small cell lung cancer cell lines is significantly enhanced by chemotherapeutic agents. Resistance and sensitization to Apo2L/TRAIL are not correlated with the endogenous expression level of cellular protease caspase-8 inhibitory protein, implying that in non–small cell lung cancer other mechanisms are responsible for inhibition of the Apo2L/TRAIL pathway. Even though the molecular mechanism remains unclear, the combination of Apo2L/TRAIL with chemotherapy may be a promising treatment modality for non–small cell lung cancer.

The Novel Akt Inhibitor Api-1 Induces C-Flip Degradation and Synergizes with Trail to Augment Apoptosis Independent of Akt Inhibition

Supplementary Figure 1 from The Novel Akt Inhibitor API-1 Induces c-FLIP Degradation and Synergizes with TRAIL to Augment Apoptosis Independent of Akt Inhibition

The E3 Ubiquitin Ligases Β-Trcp and FBXW7 Cooperatively Mediates GSK3-dependent Mcl-1 Degradation Induced by the Akt Inhibitor API-1, Resulting in Apoptosis.

The MyD88 Inhibitor, ST2825, Induces Cell Cycle Arrest and Apoptosis by Suppressing the Activation of the NF‑κB/AKT1/p21 Pathway in Pancreatic Cancer.

Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL

The Identification of New c-FLIP Inhibitors for Restoring Apoptosis in TRAIL-Resistant Cancer Cells

Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer

Pioglitazone mediates apoptosis in Caki cells via downregulating c-FLIP(L) expression and reducing Bcl-2 protein stability

Inhibition of PI3K/Akt pathway could sensitize prostate cancer (Lncap cells) to multiple apoptotic stimulus

The Discovery of Small Molecule Inhibitors of cFLIP that Sensitise Tumour Cells to TRAIL

Targeting X-linked Inhibitor of Apoptosis Protein Inhibits Pancreatic Cancer Cell Growth Through P-Akt Depletion.

Pim-2 Activates API-5 to Inhibit the Apoptosis of Hepatocellular Carcinoma Cells Through NF-κB Pathway

Digitoflavone Inhibits IκBα Kinase and Enhances Apoptosis Induced by TNFα Through Downregulation of Expression of Nuclear Factor Κb-Regulated Gene Products in Human Pancreatic Cancer Cells

Akt associates with nuclear factor kappaB and plays an important role in chemoresistance of gastric cancer cells.

A Novel Multikinase Inhibitor R8 Exhibits Potent Inhibition on Cancer Cells Through Both Apoptosis and Autophagic Cell Death

Inhibition of Akt kinase activity by a peptide spanning the betaA strand of the proto-oncogene TCL1

Triptolide-mediated Downregulation of FLIPS in Hepatoma Cells Occurs at the Post-Transcriptional Level Independently of Proteasome-Mediated Pathways

XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis

Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein.

A novel triptolide analog downregulates NF-kB and induces mitochondrial apoptosis pathways in human pancreatic cancer

Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK/ERK and PI3K/AKT pathways